Table 2.

Clinical considerations for the management of CVD risk using SGLT2i therapies in people with T2DM [1, 42–48, 57–59, 77, 78, 80, 81, 86]

CVD cardiovascular disease, DKA diabetic ketoacidosis, eGFR estimated glomerular filtration rate, HF heart failure, MACE major adverse cardiovascular events, T2DM type 2 diabetes mellitus

*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m². Individuals already treated with an SGLT2i therapy who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m²